Business Description

Emmaus Life Sciences Inc
NAICS : 325414 SIC : 2836
ISIN : US62857N2027
https://www.emmausmedical.com
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Compare
Compare
SILOADTXGNPXZVSASONNENSCKAXBIOTTNPSCPXOCSE:NOVO BVRTXREGNASX:CSLXKRX:207940MRNAXKRX:068270XBRU:ARGXXBRU:UCBBNTX
Traded in other countries / regions
EMMA.USA
IPO Date
2011-02-23
Description
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.04
Equity-to-Asset -0.77
Debt-to-Equity -0.97
Debt-to-EBITDA 17.33
Interest Coverage 0.11
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.12
Distress
Grey
Safe
Beneish M-Score -1.67
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -11.6
3-Year EBITDA Growth Rate 44.2
3-Year EPS without NRI Growth Rate 36.7
3-Year FCF Growth Rate 1.6
3-Year Book Growth Rate -44.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 47.89
9-Day RSI 46.42
14-Day RSI 47.32
6-1 Month Momentum % -25
12-1 Month Momentum % -73.53

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.15
Quick Ratio 0.12
Cash Ratio 0.02
Days Inventory 438.89
Days Sales Outstanding 36.5
Days Payable 819.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.8
Shareholder Yield % -84.59

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 93.69
Operating Margin % 2.7
Net Margin % -16.66
FCF Margin % -3.1
ROA % -10
ROIC % 0.96
ROC (Joel Greenblatt) % 72.27
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.2
EV-to-EBIT 19.6
EV-to-EBITDA 19.22
EV-to-Revenue 1.38
EV-to-FCF -44.49
Price-to-Median-PS-Value 0.03
Earnings Yield (Greenblatt) % 5.1
FCF Yield % -16.42

Financials (Next Earnings Date:2024-05-15 Est.)

EMMA's 30-Y Financials
AAPL
Income Statement Breakdown
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:EMMA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Emmaus Life Sciences Inc Executives

Details

GF Value: $0.71

EMMA

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 28.46
EPS (TTM) ($) -0.09
Beta 1.81
Volatility % 59.37
14-Day RSI 47.32
14-Day ATR ($) 0.006694
20-Day SMA ($) 0.104629
12-1 Month Momentum % -73.53
52-Week Range ($) 0.0506 - 0.34
Shares Outstanding (Mil) 53.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Emmaus Life Sciences Inc Filings

Filing Date Document Date Form
No Filing Data

Emmaus Life Sciences Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Emmaus Life Sciences Inc Frequently Asked Questions

What is Emmaus Life Sciences Inc(EMMA)'s stock price today?
The current price of EMMA is $0.10. The 52 week high of EMMA is $0.34 and 52 week low is $0.05.
When is next earnings date of Emmaus Life Sciences Inc(EMMA)?
The next earnings date of Emmaus Life Sciences Inc(EMMA) is 2024-05-15 Est..
Does Emmaus Life Sciences Inc(EMMA) pay dividends? If so, how much?
Emmaus Life Sciences Inc(EMMA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.